TECELRA (afamitresgene autoleucel)
TherapyAdaptimmune
TECELRA (afamitresgene autoleucel) from Adaptimmune is a T-cell therapy used in MAGE-A4–expressing synovial sarcoma.
Approvals
2
Indications
1
Biomarkers
2
Mapped tests
2
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TECELRA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where TECELRA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Synovial sarcoma Solid Tumor · Soft Tissue | Melanoma-associated antigen 4 (MAGE-A4)
| View testing pathway → | |
Synovial sarcoma Solid Tumor · Soft Tissue | HLA
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TECELRA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TECELRA for eligible patients.
Test
MAGE-A4 IHC 1F9 pharmDx
Agilent Technologies, Inc.
Method
IHC
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
SeCore CDx HLA Sequencing System
One Lambda, Inc. (ThermoFisher Scientific)
Method
SANGER
Specimen
Whole blood
1 approvalView test profile →